Stephens lowered the firm’s price target on Hologic (HOLX) to $70 from $77 and keeps an Overweight rating on the shares. Shares traded down after a “disappointing” fiscal Q2 report, notes the analyst, who thinks a lack of catalysts could keep shares range bound in the near-term. However, at the current valuation, the firm feels moderated near-term growth is priced in and thinks there’s likely more upside than downside over the next 12 months, but this relies on execution in breast health, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic price target lowered to $65 from $77 at Morgan Stanley
- Hologic’s Hold Rating: Balancing Growth in Diagnostics with Challenges in Breast Health and Geopolitical Pressures
- Hologic’s Financial Outlook: Hold Rating Amid Revenue Decline and Tariff Challenges
- Hologic’s Earnings Call: Balancing Growth and Challenges
- Hologic price target lowered to $71 from $90 at Raymond James